Clinical Trials

Sponsor: Shanghai Fosun Pharmaceutical Development Co, Ltd.

Sponsor Study ID: FCN-159-002

Study Title: A Multi center, Open label, Single arm Phase I Dose escalation and Phase II Dose expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti tumor Activity of FCN 159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

NCT Number: NCT04954001

Phase: I/II

Protocol Type: Treatment

Age Group: Adult and Children

Disease Sites: Brain and Nervous System

Study Objectives: FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib. FCN-159 is an orally available and highly potent selective inhibitor of MEK1/2, which is expected to be a targeted therapy for the treatment of advanced solid tumors and neurofibromatosis type 1.



For more information about the trial above please contact the study team:

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)